.
MergerLinks Header Logo

Announced

Alcon to acquire Ivantis for $475m.

Financials

Edit Data
Transaction Value£352m
Consideration TypeCash, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Majority

Private

Acquisition

Friendly

Pending

United States

glaucoma treatment

Cross Border

Medical Equipment

Synopsis

Edit

Alcon, a company provides eye care, agreed to acquire Ivantis, a minimally invasive glaucoma surgical solutions developer, for $475m. “Glaucoma is the second-largest cause of blindness after cataracts, impacting more than 75 million people globally, with significant unmet patient need. This transaction will allow us to add a uniquely effective product into our glaucoma portfolio around the world. Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent," David Endicott, Alcon CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US